Digital health startup Transcarent takes Accolade private in $621 million deal
Digital health startup Transcarent takes Accolade private in $621 million deal
Accolade and Transcarent announce expiration of Hart-Scott Rodino waiting period for pending merger transaction
Transcarent to acquire Accolade in $621M deal
Accolade gains on report of takeover interest
Ian Allison's Giant Sam Bankman-Fried Scoop Won Accolades in 2023
#earnings after the close https://t.co/lObOE0dgsr $AMZN $INTC $SNAP $NET $FSLR $PINS $X $TMUS $GILD $AMGN $DXCM $SKX $COF $MDLZ $PFG $AYX $SAM $LHX $DLR $SWN $BJRI $AEM $SGEN $ACCD $FICO $IMAX $WY $RMD $ALSN $VRSN $KNSL $CINF $CAMP $CUBE $MHK $CC $CSL $APPF $SKYW $SLCA $HIG $SM… https://t.co/fgu6udfLVA
575.59MUSD
See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US00437E1029
CUSIP
M01690102
Sector
Healthcare
Industry
Health Information Services
Fiscal Year End
February
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
-
Book Value
3.86
Dividend Share
-
Dividend Yield
-
Earnings Share
-2.28
Wall Street Target Price
7.03
EPS Estimate Current Year
-0.27
EPS Estimate Next Year
-0.20
EPS Estimate Current Quarter
-0.16
EPS Estimate Next Quarter
0
Most Recent Quarter
-
Revenue TTM
446,718,016
Gross Profit TTM
215,083,008
EBITDA
-47,624,000
Profit Margin
-40.36%
Return On Assets TTM
-7.50%
Return On Equity TTM
-48.23%
Revenue Per Share TTM
5.723
Qtly Revenue Growth YOY
5.70%
Diluted Eps TTM
-2.28
Qtly Earnings Growth YOY
0.00%
Trailing PE
0.00
Forward PE
0
Price Sales TTM
1.2885
Price Book MRQ
1.839
Enterprise Value Revenue
1
Enterprise Value EBITDA
-11
58.75
3.65%86.90
3.00%229.56
1.77%17.51
1.21%37.04
1.11%68.77
1.02%54.14
0.82%23.41
0.82%118.62
0.00%6.23
-2.04%